Developer docs
API playgroundTry for free, no card

Search company profiles

Bay City Capital

Full company profile

uuid000722b

Namestring
Bay City Capital
Websiteurl
http://www.baycitycapital.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Bay City Capital LLC is a privately held investment firm founded in 1997 and headquartered in San Francisco, California, that specializes in investments in the life sciences industry. The firm operates as a boutique, sector-focused capital allocator rather than a product or technology company, meaning its "product" is the investment vehicle and the associated services rendered to portfolio companies and limited partners. Its core business activity is the deployment of capital into life sciences opportunities, drawing on a senior team that includes multiple Managing Directors (Lionel Carnot, David Beier, Fred Craves) and dedicated finance and operating leadership (Judy Koh as Managing Director/Chief Financial Officer, Susan Vuong as CFO, Matt Kronmiller as Vice President, and Marge Josephson as Vice President of Human Resources and Operational Services).

The firm runs a lean operating model with 11-50 employees, consistent with the resource profile of a specialist private investment manager where value is concentrated in the investment committee and partner network rather than in large operational headcount. As a private investment firm, Bay City Capital's revenue mechanics are not disclosed in the source data, but are structurally derived from management fees on committed/raised fund capital and, where applicable, carried interest on realized investment gains; no fund sizes, vintage years, AUM, fee schedules, or portfolio company counts were observable in the inputs. There is no publicly disclosed product line, technology platform, pricing model, customer segment, or geographic footprint beyond the U.S. headquarters, and the firm operates without a parent company, subsidiaries, or disclosed ownership.

The principal data limitation for this profile is that the firm's website returned only a verification/loading page, and no first-party disclosures on fund vintages, AUM, recent transactions, partnerships, or awards were available to corroborate or extend the basic firmographic record.

Short descriptiontext

Bay City Capital is a San Francisco-based private investment firm founded in 1997 that specializes in life sciences investments, deploying capital through a boutique structure led by a team of managing directors and dedicated operating leadership.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
life sciences venture capital, biotech investment, healthcare private equity, pharmaceutical venture funding, medical device investment
Industry2 codes
1Geography-Focused Venture Capital (Regional/Emerging Markets)
CodeFSANAAAEPrimaryYes
2Corporate Strategic Real Assets & Infrastructure Venture Investing
CodeFSANAHANPrimaryNo
NAICS code2 codes
  • Other Financial Investment Activities5239
  • Corporate, Subsidiary, and Regional Managing Offices551114
SIC code1 code
  • Investors, Nec6799
Product category
Life Sciences Venture Capital
Social media profiles2 records
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bay City Capital LLC is a private venture capital and private equity firm founded in 1997 that invests in the life sciences industry. The firm provides equity capital to privately held life sciences companies, including biotechnology, pharmaceutical, and medical device businesses, in exchange for equity stakes and the prospect of investment returns. It is headquartered in San Francisco and operates with a small team of managing directors and supporting staff.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Life Sciences Venture Capital Investment
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment142 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bay City Capital

Life Sciences Venture Capitalbaycitycapital.com

Bay City Capital is a San Francisco-based private investment firm founded in 1997 that specializes in life sciences investments, deploying capital through a boutique structure led by a team of managing directors and dedicated operating leadership.

What Bay City Capital does

Bay City Capital LLC is a privately held investment firm founded in 1997 and headquartered in San Francisco, California, that specializes in investments in the life sciences industry. The firm operates as a boutique, sector-focused capital allocator rather than a product or technology company, meaning its "product" is the investment vehicle and the associated services rendered to portfolio companies and limited partners. Its core business activity is the deployment of capital into life sciences opportunities, drawing on a senior team that includes multiple Managing Directors (Lionel Carnot, David Beier, Fred Craves) and dedicated finance and operating leadership (Judy Koh as Managing Director/Chief Financial Officer, Susan Vuong as CFO, Matt Kronmiller as Vice President, and Marge Josephson as Vice President of Human Resources and Operational Services).

The firm runs a lean operating model with 11-50 employees, consistent with the resource profile of a specialist private investment manager where value is concentrated in the investment committee and partner network rather than in large operational headcount. As a private investment firm, Bay City Capital's revenue mechanics are not disclosed in the source data, but are structurally derived from management fees on committed/raised fund capital and, where applicable, carried interest on realized investment gains; no fund sizes, vintage years, AUM, fee schedules, or portfolio company counts were observable in the inputs. There is no publicly disclosed product line, technology platform, pricing model, customer segment, or geographic footprint beyond the U.S. headquarters, and the firm operates without a parent company, subsidiaries, or disclosed ownership.

The principal data limitation for this profile is that the firm's website returned only a verification/loading page, and no first-party disclosures on fund vintages, AUM, recent transactions, partnerships, or awards were available to corroborate or extend the basic firmographic record.

Bay City Capital firmographics

Firmographics
Name
Bay City Capital
Website
http://www.baycitycapital.com
Company type
Private
Founded year
1997
Headcount range
11–50 employees
Short description
Bay City Capital is a San Francisco-based private investment firm founded in 1997 that specializes in life sciences investments, deploying capital through a boutique structure led by a team of managing directors and dedicated operating leadership.
Ownership category
akta.pro rank

Bay City Capital industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Other Financial Investment Activities (5239), Corporate, Subsidiary, and Regional Managing Offices (551114)
SIC
Investors, Nec (6799)
akta.pro primary industry
Geography-Focused Venture Capital (Regional/Emerging Markets) (FSANAAAE)
akta.pro secondary industry
Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

  • Life sciences venture capital
  • Biotech investment
  • Healthcare private equity
  • Pharmaceutical venture funding
  • Medical device investment

Where Bay City Capital is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Bay City Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Bay City Capital product offering

Product offering

Core offering

Bay City Capital LLC is a private venture capital and private equity firm founded in 1997 that invests in the life sciences industry. The firm provides equity capital to privately held life sciences companies, including biotechnology, pharmaceutical, and medical device businesses, in exchange for equity stakes and the prospect of investment returns. It is headquartered in San Francisco and operates with a small team of managing directors and supporting staff.

Differentiator

Problem solved

Functional benefit

Products and services

  • Life Sciences Venture Capital Investment

Companies that use Bay City Capital

Customer profile

Ideal customer profiles1 record

Bay City Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Bay City Capital partnerships and signals

Strategic signal

Recent moves2 records

Bay City Capital competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Bay City Capital social profiles

Digital presence

Bay City Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bay City Capital leadership team

Management profile

Number of profiles

Profiles7 records

Bay City Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bay City Capital M&A and investment

M&A and investment

M&A

Investments142 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bay City Capital

What does Bay City Capital do?

Bay City Capital LLC is a private venture capital and private equity firm founded in 1997 that invests in the life sciences industry. The firm provides equity capital to privately held life sciences companies, including biotechnology, pharmaceutical, and medical device businesses, in exchange for equity stakes and the prospect of investment returns. It is headquartered in San Francisco and operates with a small team of managing directors and supporting staff.

When was Bay City Capital founded?

Bay City Capital was founded in 1997. It employs 11 to 50 people.

Where is Bay City Capital based?

Bay City Capital is headquartered in San Francisco, United States, in the North America region.

Does Bay City Capital have an API?

No public API is recorded for Bay City Capital.

What industry is Bay City Capital in?

Bay City Capital's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAE, Geography-Focused Venture Capital (Regional/Emerging Markets), with a secondary code of FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 5239 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMadrigal Pharmaceuticals Announces Secondary Offering ofMadrigal Pharmaceuticals announced a secondary offering of 1,200,000 shares by investment funds affiliated with Bay City Capital LLC, with Goldman Sachs as book manager. The company will not receive proceeds from the sale. The offering is under an effective shelf registration statement filed with the SEC.PR NewswireMenlo Therapeutics Raises $50MMenlo Therapeutics Inc. announced the completion of a $50M Series C financing round led by venBio, with participation from new investors Novo Holdings A/S, Rock Springs Capital, Aisling Capital, and Bay City Capital, along with existing investors Vivo Capital, Presidio Partners, Remeditex, and F-Prime Capital. The funding will advance clinical development of serlopitant, a novel NK-1 receptor antagonist, across four indications including prurigo nodularis (Phase 3 trials planned H1 2018), atopic dermatitis (Phase 2 enrolling), psoriasis, and refractory chronic cough. The drug candidate demonstrated statistically significant reduction in pruritus across two completed Phase 2 trials conducted in the United States and Germany, involving 257 and 127 subjects respectively.PR NewswireTwist Bioscience Raises Additional $27 MillionTwist Bioscience Corporation announced it raised an additional $27 million in venture financing, completing a $60 million total financing round. The funding brings the company's total raised capital to $191 million and will support expansion of its core gene synthesis business and investment in drug discovery and DNA digital data storage. The round included strategic investors such as Biomatics Capital as well as new investors including Reinet Fund, NFT Investment, KANGMEI Group, Bay City Capital, 3W Partners Capital and Ditch Plains Capital.FinSMEsSynGen Secures Additional Financing from Bay City CapitalSynGen, a stem cell processing developer, secured additional financing from Bay City Capital, bringing total investment to $10M. The funds will support first sales of the SynGenX-1000 System to cord blood banks and commercialization of other devices. Additional funds may be available subject to milestones.FinSMEsCydan Raises $10M FundingCydan, a Cambridge-based orphan drug accelerator, raised an additional $10M in funding led by Lundbeckfond Ventures and Bay City Capital. The company will use the funds to de-risk assets and launch new companies focused on rare diseases. Lundbeckfond Ventures and Bay City Capital partners are joining Cydan's board.FinSMEsCivitas Therapeutics Completes $38M Series B FinancingCivitas Therapeutics completed a $38M Series B financing led by Bay City Capital. The funds will support late-stage clinical development of CVT-301, an inhaled levodopa for Parkinson's motor fluctuations, and explore ARCUS platform opportunities. The company initiated a Phase 2b study and will report preliminary data in the first half of 2014.FinSMEsNabsys Closes $20M Series D FinancingNabsys, a Providence, RI-based life sciences company, closed a $20 million Series D financing led by Bay City Capital with participation from Point Judith Capital and Stata Venture Partners. The company will use the funds to launch its positional sequencing system for genome assembly and structural variation analysis.FinSMEsUSA, Epizyme Closes $32M Series B FinancingEpizyme closed a $32M Series B financing led by Bay City Capital, with participation from Amgen Ventures, Astellas Venture Management, and existing investors. Carl Goldfischer, a BCC partner, joined the company's board of directors.